Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioning

27 Jun 2024

Abstract excerpt

Hematopoietic stem cell transplantation (HSCT) is widely used to treat patients with life-threatening hematologic and immune system disorders. Current nontargeted chemo-/radiotherapy conditioning regimens cause tissue injury and induce an array of immediate and delayed adverse effects, limiting the application of this life-saving treatment. The growing demand to replace canonical conditioning regimens has led to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39822756
DOI: 10.1016/j.omton.2024.200843

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting CD45 by gene-edited CAR T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioningPMID 39822756Read ↗

Targeting CD45 by gene-edited CAR-T cells for leukemia eradication and hematopoietic stem cell transplantation preconditioningSemantic proximity Read ↗

Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cellsSemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemiaSemantic proximity Read ↗

Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignanciesSemantic proximity Read ↗

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell MalignanciesSemantic proximity Read ↗

Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene TherapySemantic proximity Read ↗

Current status and perspective of CAR-T and CAR-NK cell therapy trials in GermanySemantic proximity Read ↗

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML TherapySemantic proximity Read ↗

Chimeric Antigen Receptor T-cell Therapy to Target Hematologic MalignanciesSemantic proximity Read ↗

CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapySemantic proximity Read ↗

Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.